These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 9125864)

  • 1. [Determination of urinary CA19-9 levels in urothelial cancer--assessment of its role in diagnosis].
    Noto K; Fujime M; Isobe H; Wakumato Y; Kawachi Y
    Nihon Hinyokika Gakkai Zasshi; 1997 Mar; 88(3):406-13. PubMed ID: 9125864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary level of CA19-9 as a tumor marker in urothelial carcinoma of the bladder.
    Pal K; Roy S; Mondal SA; Chatterjee U; Tiwari P; Bera M
    Urol J; 2011; 8(3):203-8. PubMed ID: 21910099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group].
    Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
    Gan To Kagaku Ryoho; 1997 May; 24(7):837-42. PubMed ID: 9170522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The clinical usefulness of urinary basic fetoprotein (BFP) in patients with urological malignancies].
    Tsujii T; Yonese J; Kojima S; Tari K; Ishii M; Seino Y
    Nihon Hinyokika Gakkai Zasshi; 1990 Jun; 81(6):829-34. PubMed ID: 1698231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue polypeptide antigen and carcinoembryonic antigen lack diagnostic accuracy in urothelial carcinoma.
    Stefanović V; Mitić-Zlatković M; Ignjatović I; Vlajković M; Sćepović Z
    Int Urol Nephrol; 1999; 31(4):443-9. PubMed ID: 10668938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--NMP22 as a urinary marker for surveillance of bladder cancer. NMP22 Study Group].
    Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
    Gan To Kagaku Ryoho; 1997 May; 24(7):829-36. PubMed ID: 9170521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A case of CA19-9 producing transitional cell carcinoma of the ureter].
    Yamamoto H; Ueda Y; Maruyama T; Kondou N; Nojima M; Takiuchi H; Mori Y; Shima H; Kubota A
    Hinyokika Kiyo; 2003 Sep; 49(9):543-5. PubMed ID: 14598694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of urinary CA19-9 levels in bladder cancer patients classified according to the combinations of Lewis and Secretor blood group genotypes.
    Nagao K; Itoh Y; Fujita K; Fujime M
    Int J Urol; 2007 Sep; 14(9):795-9. PubMed ID: 17760744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of urinary and serum CA 19-9 as markers of early stage urothelial carcinoma.
    Roy S; Dasgupta A; Kar K
    Int Braz J Urol; 2013; 39(5):631-8. PubMed ID: 24267106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of carbohydrate antigens (SSEA-1, sialyl-Lewis X, DU-PAN-2 and CA19-9) and E-selectin in urothelial carcinoma of the renal pelvis, ureter, and urinary bladder.
    Kajiwara H; Yasuda M; Kumaki N; Shibayama T; Osamura Y
    Tokai J Exp Clin Med; 2005 Sep; 30(3):177-82. PubMed ID: 16285609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pancreatic secretory trypsin inhibitor in urothelial cancer].
    Tashiro K; Torii S; Iwamuro S; Ohishi Y; Hasegawa N; Kawashima Y; Mochizuki A; Yoshigoe H; Wada T; Machida T
    Hinyokika Kiyo; 1989 Oct; 35(10):1659-63. PubMed ID: 2610172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The clinical significance of carbohydrate antigen 19-9 (CA19-9) in transitional cell cancer of urinary tract].
    Kurokawa K; Kurihara J; Nakata S; Matsuo Y; Ebihara K; Kurihara H; Suzuki T; Imai K; Yamanaka H; Suzuki K
    Nihon Hinyokika Gakkai Zasshi; 1993 Jun; 84(6):1074-81. PubMed ID: 8345724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of CA19-9 in predicting the prognosis of urothelial carcinoma: a hospital based study from Nepal.
    Jha DK; Mittal A; Gupta SP; Sathian B
    Asian Pac J Cancer Prev; 2013; 14(7):4067-9. PubMed ID: 23991954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasmacytoid/diffuse urothelial carcinoma: a single-institution immunohistochemical and molecular study of 69 patients.
    Perrino CM; Eble J; Kao CS; Whaley RD; Cheng L; Idrees M; Hashemi-Sadraei N; Monn MF; Kaimakliotis HZ; Bandali E; Grignon D
    Hum Pathol; 2019 Aug; 90():27-36. PubMed ID: 31054897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ureteral cancer producing carbohydrate antigen 19-9: report of a case].
    Segawa N; Yamamoto K; Watsuji T; Suzuki T; Ueda H; Katsuoka Y
    Hinyokika Kiyo; 1997 Sep; 43(9):665-8. PubMed ID: 9365848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of CA19-9 as a tumor marker in urothelial malignancy.
    Chuang CK; Liao SK
    Scand J Urol Nephrol; 2004; 38(5):359-65. PubMed ID: 15764245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary cytology and the clinical diagnosis of urinary tract malignancy: a clinicopathologic study of 1,400 patients.
    Sarnacki CT; McCormack LJ; Kiser WS; Hazard JB; McLaughlin TC; Belovich DM
    J Urol; 1971 Nov; 106(5):761-4. PubMed ID: 4107230
    [No Abstract]   [Full Text] [Related]  

  • 19. Fluorescence in situ hybridization (FISH) in the diagnosis of bladder and upper tract urothelial carcinoma: the largest single-institution experience to date.
    Gomella LG; Mann MJ; Cleary RC; Hubosky SG; Bagley DH; Thumar AB; McCue PA; Lallas CD; Trabulsi EJ
    Can J Urol; 2017 Feb; 24(1):8620-8626. PubMed ID: 28263126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ureteropyeloscopic diagnosis and treatment of upper urinary tract urothelial malignancies.
    Grasso M; Fraiman M; Levine M
    Urology; 1999 Aug; 54(2):240-6. PubMed ID: 10443718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.